Sign in to fuzzto save your conversations, follow your research and come back anytime.
Yatharth Hospital
SectorHealthcare
The Quarter story
The two most recent quarterly results, compared side-by-side.
Yatharth Hospital scales capacity and revenue rapidly, though margin compression reflects the cost of aggressive expansion.
Revenue grew from ₹2,578 in Q1 FY26 to ₹3,927 in Q1 FY27, fueled by new hospital openings and volume growth.
PAT margin contracted from 16.3% in Q1 FY26 to 11.6% in Q1 FY27, pressured by higher financial and operational costs.
Bed capacity expanded from 1,605 in Q1 FY26 to 2,800 in Q1 FY27, demonstrating aggressive infrastructure scaling.
Financial cost spiked from ₹2 in Q1 FY26 to ₹66 in Q1 FY27, signaling increased leverage to fund capacity expansion.
Average revenue per occupied bed rose from ₹32,395 in Q1 FY26 to ₹34,758 in Q1 FY27, reflecting strong pricing power.
Employee expenses grew from ₹482 in Q1 FY26 to ₹779 in Q1 FY27, reflecting necessary hiring for new hospital openings.
Patient volume increased from 124,000 in Q1 FY26 to 169,000 in Q1 FY27, confirming robust demand across services.
Other expenses climbed from ₹916 in Q1 FY26 to ₹1,537 in Q1 FY27, driven by scaling operational overheads.
Occupancy improved from 65% in Q1 FY26 to 68% in Q1 FY27, showing healthy utilization despite rapid expansion.
Adjusted EBITDA margin declined from 29.2% in Q3 FY26 to 28.1% in Q1 FY27, indicating slight profitability compression.
Company insights, generated from the most recent coverage.
Yatharth's own capex plan is ~70% acquisitions / 30% greenfield, at Rs 60-70 lakh per bed brownfield versus about Rs 1 crore per bed greenfield — a 30-40% cheaper route to its 5,000-bed target.
Advent's operating partner model expected to drive 600-875 bps EBITDA margin expansion through supply chain optimization, lean processes, and revenue enhancement strategies.
Partnership shifts Yatharth's perception from regional player to institutional healthcare platform, enhancing ability to attract senior clinical talent and institutional investors.
